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Angina Caused by Reduced Vasodilator Reserve of the Small
Coronary Arteries
RICHARD O. CANNON III, MD, RITA M. WATSON, MD, DOUGLAS R. ROSING, MD, FACC,
STEPHEN E. EPSTEIN, MD, FACC
Bethesda, Maryland
To study the mechanism of chest pain in patients with
insignificant large vessel coronary artery disease, 22 pa-
tients underwent great cardiac vein flow, coronary re-
sistance and lactate determinations at rest and with coro-
nary sinus pacing followed by coronary arteriography.
Nine patients experiencing chest pain with pacing dem-
onstrated significantly lesser increase in flow from base-
line values (45 ± 30 versus 86 ± 50% [mean ± standard
deviation], p < 0.025), lesser decrease from baseline in
resistance (-28 ± 18 versus -44 ± 11%, p < 0.001)
and less lactate consumption (25.0 ± 23.6 versus 45.6
± 19.0 mmol-ml/min, p < 0.025) compared with the
13 patients without pacing-induced chest pain. Pacing
conducted during the cold pressor test elicited similar
abnormalities in those patients experiencing chest pain
and those who did not: four of eight patients experiencing
chest pain demonstrated a lowered or new anginal
threshold compared with that of the control pacing study.
Coronary arteriography during the cold pressor test re-
vealed no significant change in epicardial coronary ar-
tery dimension.
After administration of ergonovine, 0.15 mg intra-
venously, 2 of 20 patients experienced spontaneous chest
pain, which was associated with the greatest decrease in
The occurrence of chest pain despite arteriographic dem-
onstration of normal coronary anatomy or insignificant coro-
nary artery disease continues to be a perplexing and frus-
trating experience for both the patient and physician. The
fact that up to 30% of patients referred for diagnostic coro-
nary arteriography (1-5) exhibit this "syndrome" attests to
its frequency. Multiple explanations (6,7) have been offered
to account for these findings, including incorrect interpre-
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flow ( - 13 and - 21%, respectively) and increase in re-
sistance (+26 and +39%, respectively) of any patient.
Pacing resulted in chest pain in 10 of the remaining 18
patients, including 5 patients who had not experienced
chest pain during the control pacing study. Although
none of these patients exhibited significant epicardial
coronary artery narrowing on arteriography, their flow
increased less (38 ± 12 versus 126 ± 68%, p < 0.001),
resistance decreased less ( - 18 ± 4 versus - 50 ± 13%,
P < 0.001) and was associated with less lactate con-
sumption (32.7 ± 25.2 versus 70.1 ± 29.4 mmol-ml/min,
p < 0.01) than in patients not experiencing chest pain.
Eight of the 12 patients developing chest pain demon-
strated a decreased or new anginal threshold compared
with that elicited by pacing during the control study.
These findings suggest that some patients with atyp-
ical chest pain have inappropriate coronary arteriolar
or small coronary artery constriction with abnormal vaso-
dilator reserve in response to atrial pacing. The abnor-
mality can be unmasked or exacerbated in some patients
by vasoconstrictor stimuli, but cannot be identified with
standard angiographic assessment of "spasm" because
abnormal vasoconstriction occurs in vessels too small to
be visualized by angiography.
tation of the arteriogram and alternative conditions such as
hypertrophic cardiomyopathy, myocardial bridging, mus-
culoskeletal syndrome, mitral valve prolapse or chest pain
of psychosomatic origin (8-10). Although the survival of
these patients appears to be good, some patients with chest
pain and normal coronary arteriograms have experienced
myocardial infarction, have died suddenly or have remained
limited in activity, continuing to utilize health care resources
(1,11-14).
Coronary artery spasm accounts for chest pain in a seg-
ment of this group of patients. Current diagnostic testing
for coronary spasm employs a vasoconstrictor maneuver,
such as ergonovine (15) or cold pressor test (16) during
coronary arteriography, in an attempt to identify total or
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subtotal reversible epicardial coronary artery narrowing as-
sociated with the appearance of chest pain. Nonetheless,
although such a "positive test " for coronary artery spasm
occurs frequently in those patients whose rest pain is as-
sociated with ST segment alterations on electrocardio-
graphic monitoring, it is uncommon in all other subjects
(17), leaving a large number of patients with unexplained
chest pain .
Our observation of the failure of standard ergonovine
testing to precipitate coronary artery spasm in patients with
normal or near normal coronary arteries who are severel y
limited by chest pain prompted us to measure regional coro-
nary blood flow and resistance to determine whether the
pain experienced by these patients might be due to con-
striction of coronary vessels too small to be seen by
arteriography.
Methods
Study group. Thirty-one consecutive patients referred
to the Cardiology Branch of the National Heart, Lung , and
Blood Institute for evaluation of atypical chest pain were
considered for entry into the study. Patients were considered
eligible for study if their chest pain had a variable threshold
of onset: although exertion often precipitated the pain, the
amount of exercise associated with onset of pain was vari-
able . More patients also experienced rest pain. However ,
none of 28 patients in whom an electrocardiogram was ob-
tained during an episode of chest pain exhibited ST segment
shifts . All patients had undergone previous diagno stic coro-
nary arteriography; 16 patients had normal coronary arteries ,
2 had significant coronary artery disease in the circumflex
artery distribution only (Patients 3 and 20; Table 1), 1patient
had significant right coronary artery disease only (Patient
21) and I patient had undergone coronary bypass surgery
with widely patent grafts and no significantly diseased non-
bypassed vessels (Patient 12). Three patients had extensive
left anterior descending coronary artery disease and were
excluded from the study . The remaining patients had insig-
nificant « 50% luminal diameter narrowing) coronary ar-
tery disease representing , in the majority of cases . only
minor vessel wall irregularities.
Five patients (three of whom had insignificant epicardial
coronary disease) had a history of myocardial infarction
documented by cardiac enzyme changes as reported by their
referring physicians (Patients 12, 17, 18, 19 and 21). Five
patient s had an abnormal 12 lead electrocardiogram (con-
duction abnormalities in three , widespread ST segment ab-
normalities in another and Q waves across the precordium
in another) . No patient had an abnormal treadmill exercise
test by history, and 25 had undergone extensive gastroin-
testinal evaluation without identification of an alternative
explanation for their chest pain . Eight patients (Patients I,
6,7 , II , 14, 15, l7and 19) had a history of mild diastolic
hypertension, although no patient was found to have a di-
astolic blood pressure greater than 90 mm Hg or systolic
blood pressure greater than 160 mm Hg when not taking
medication at the time of entry into the study . Patient I had
a history of migraine headache s and Patient 21 had a history
of Raynaud' s phenomena. Three patient s (Patients 8, 16 and
17) had insulin-requiring diabetes mellitu s. Four patients
(Patient s 10. 15, I7 and 18) had a history of cigarette use
of less than 30 packs per year : none smoked within I year
of entry into the study . All patients had previously been
managed with standard antianginal medications, including
long-acting nitrates and beta-adrenergic blocking agents with
unsatisfactory results; 12 had even manifested an increase
in frequency of chest pain.
After admission, each patient underwent a thorough his-
tory and physical examination , with attention to a muscu-
loskeletal cause of their chest pain (10). Routine blood work,
electrocardiogram, chest X-ray film, M-mode echocardio-
gram and graded bicycle exercise testing using a National
Institutes of Health protocol (18) were performed on all
patient s; patients remained on telemetry throughout their
hospitalization. This study was approved by the Clinical
Research Subpanel of the National Heart , Lung, and Blood
Institute on May 4 , 1981. Informed con sent was obtained
from all patients .
Experimental protocol. Except for sublingual nitrogl yc-
erin , all medications were discontinued at least 24 hours (or
5 drug half-lives) before cardiac catheterization. After an
overnight fast . a thermodilution pacing catheter (Elecath)
(19) was introduced into the right atrium percutaneously by
way of the right internal jugular vein. In 22 of the 28 patients
considered eligible for study, the catheter was successfully
advanced into the great cardiac vein, which drains approx-
imately 90% of the blood flowing through the left anterior
descending coronary artery (20 ,21) . In six patients, the great
cardiac vein could not be entered, terminating the study in
this group . Catheter position was verified initially by small
injections of contrast material and kept constant throughout
the study as determined by fluoroscopy before every great
cardiac vein flow measurement.
The thermodilution technique fo r determining great car-
diac vein flow has been described previously (19.21 ,22).
Coronary resistance was calculated as the mean arterial pres-
sure divided by great cardiac vein flow. Coronary sinus flow
measurements were not recorded becau se of concern for
possible right atrial reflux (23). A left coronary artery cath-
eter was introduced percutaneously by way of the femoral
artery and advanced to the aortic arch for measurement of
blood pressure . In the last eight patient s entered in the study,
a Swan-Ganz thermodilution catheter (Edwards Laborato-
ries) was advanced into the pulmonary artery for cardiac
output and pulmonary capillary wedge pressure determi-
nation . Arterial pressure and the electrocardiogram from
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mon itor leads I, II and III were alway s recorded simulta-
neously with all great cardiac vein flow measurements.
Lactate samples were obtained from the great cardiac
vein through the distal port of the thermodilution catheter
and from the arterial catheter at the beginning and end of
each study . Specimens were anal yzed on a DuPont auto-
matic clin ical anal yzer by a modification of the technique
of Marbach and Weil (24) . Lactate consumption was cal-
culated as great cardiac vein flow multiplied by the differ-
ence between arteri al and great cardiac vein lactate
concentrations.
Control study. After baseline great cardiac vein flow
and arterial pressure measurements (at least 30 minutes after
contrast injection for catheter placement) were obtained,
pacing was initiated by means of the thermodilution catheter
at 100 beats/min . These measurements were repeated at I
minute intervals at which time the pacing rate was increased
by 10 beats/min . Atrio ventricular node block occurred in
seven patients. Atrop ine , 0 .5 to 1.0 mg intravenously, was
admini stered to four of these patients who . along with the
rema ining patients , underwent sequential pacing to a heart
rate of 150 beats/min which term inated the control study.
Selective coronary arteri ograph y of the left and right coro-
nary arteries was then performed.
Cold pressor test. After a minimal rest period of 15
minute s to allow any contrast-induced alterations in coro-
nary blood flow to subside, repeat baseline great card iac
vein flow , arterial pressure and lactate measurements were
obtained. The patient ' s left hand was then immersed to the
wrist in ice water, and after 30 seconds the great cardiac
vein flow and arterial pressure were recorded . Pacing was
then initiated, with the patient' s hand still immersed in ice
water, at 20 beats/min lower than the heart rate at which
chest pain occurred in the control study. If no chest pain
was experienced during the control study, the heart rate was
started at 20 beats/min lower than the control study final
heart rate. Atropine was administered to the same four pa-
tients as in the control study. At I minute interval s, repeat
great cardiac vein flow and arterial pressure measurements
were recorded and the pacing rate was increased by 10 beats/
min so that all patients ended the study at their control study
final heart rate . After an approximate 10 minute rest period ,
the patient 's left hand was reimmersed in ice water and
selective left and right coronary arteriography was performed.
Ergonovine test. At least 15 minutes after completion
of the cold pressor study, repeat baseline great cardiac vein
flow , arterial pressure and lactate measurements were ob-
tained . Ergonovine , 0 .15 mg , was administered intrave-
nously, and after 45 seconds repeat great cardiac vein flow
and arterial pressure measurements were obtained. Ergo-
novine was not administered to Patient 12 because of a minor
dissection of the abdominal aorta during a catheter pass (no
sequelae). Patient 20 developed spontaneous onset of atrial
fibrillation during administration of ergonovine and the study
was stopped at that point. The patient returned to sinus
rhythm spontaneously I hour later. Two patients experi-
encing chest pain underwent immediate coronary arteriog-
raphy. In a manner identical to that of the cold pressor study,
pacing was immediately initiated in the remaining 18 pa-
tients at a rate 20 beats/min lower than the heart rate at
which chest pain occurred durin g the control study, or at the
final heart rate if no chest pain was experienced durin g the
control study . Atropine was administered to the same four
patients as in the control study . At I minute interval s . repeat
great cardiac vein flow and arterial pressure measurements
were recorded and the pacing rate was increased by 10 beats/
min, so that all patients ended the study at the control study
final heart rate. Selective left and right coronary arteriog-
raphy was immediately performed after termination of pac-
ing, approximately 3 to 4 minute s after administration of
ergonovine .
Quantitative coronary arteriography. Angiograms of
the left and right coron ary arteries were always obtained in
two views 90° apart , usually 60° left anterior oblique and
30° right anterior obliqu e, using Siemens-Elema equipment
with a C arm so that the patient s were not moved dur ing
the study (previously performed diagnostic coronary arte-
riography always included multiple views, often with an-
gulation techn iques). The developed films were projected
on a Vanguard cine-projec tor at approx imately 3 x mag-
nification . Measurements of coronary artery luminal di-
ameter were made using calipers at multipl e positions alon g
the epicardial arteri es by one investiga tor who had no kno wl-
edge of the catheterization results , using the known dimen-
sion of the 8F coronary catheter as a reference measurement.
Care was taken to use frames in which the regions of interest
were centered on the screen to avoid magnification and other
distortion artifacts. Measurements made at identical points,
using branch arteries as references in the two views, were
averaged.
Statistical analysis. Data were analyzed using Student' s
t test for paired and unpaired data with a probability (p)
value less than 0 .05 considered significant. All grouped dat a
arc reported as mean ± standard deviation .
Results
Control study. The mean baseline great cardiac vein
flow before the control study (Table I) was similar to that
of previously published studies (19 ,21 ,22) using the ther-
modiluti on method . Figure I shows the great cardiac vein
flow response to pacing in all patients. In contrast to a
previous report (25) demon strating a nearly linear rise in
flow in patients with nondiseased coronary arteries , this
group of patients demonstrated a heterogeneous response .
Although flow in some patients displayed a linear increase ,
in most patients flow either reached a plateau at high er
pacing rates, or even decreased . Most of these latter patients
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Table 1. Hemodynamic Data During Control Study
Age (yr)
Rest Pacmg
Case &Sex HR BP GCY-F CR HR BP GCY-F %6GCY-F CR %6CR
Group Developing Chest Pain
I 47F 75 82 42 1.95 130 93 63 54 1.46 -22
2 53M 72 99 49 2.36 150 108 63 29 1.71 -19
3 50M 72 75 82 0.91 130 78 153 87 051 -44
4 56M 74 85 66 1.29 150 90 124 88 0.73 -44
5 54F 92 85 70 1.21 150 90 82 17 1.10 -9
6 SSM 77 122 46 2.65 150" 125 66 43 1.89 -43
7 58F 68 100 68 1.47 150" 118 106 56 1.11 -25
8 43M 74 97 57 1.70 150 109 60 5 1.82 8
9 48M 92 89 41 2.17 150 93 50 22 1.86 -13
Mean 77 93 58 1.75 146 100 85 45 1.35 -23
± SD 9 14 14 0.58 9 17 41 30 0.52 18
Group Not Developing Chest Pain
10 SSM 74 93 96 0.97 150 99 156 63 0.63 -34
II 57F 80 112 68 1.65 150 118 126 85 0.94 -43
12 52M 72 107 38 2.82 150 108 51 34 2.12 -25
13 56M 98 100 52 1.92 150 102 86 40 1.19 -38
14 54M 67 105 76 1.45 150" 114 141 86 0.81 -44
15 49M 55 108 54 2.00 150" 100 128 137 0.78 -61
16 48M 76 112 53 2.11 150 130 165 211 0.79 -58
17 48F 54 98 74 1.32 150 107 174 135 0.61 -53
18 38M 68 75 49 1.52 150 81 96 96 0.84 -45
19 48M 100 105 92 1.14 150 105 128 39 082 -28
20 64M 82 97 54 1.80 150 102 85 57 1.20 -59
21 42M 57 94 46 2.04 130 80 70 52 1.14 -44
22 47M 81 95 62 1.53 150 108 117 84 0.92 -40
Mean 74 100 63 1.71 149 104 117* 8M 0.98* -44t
± SD 15 10 18 0.48 6 13 37 50 0.37 II
P values determined comparing patients developing versus those not developing chest pain. • = p < 0.05; 'f = P < 0.025, t = p < 0.001
a = atropine; BP = mean blood pressure (mm Hgj: CR = coronary resistance (mm Hg/ml per min); %6CR = percent change in coronary resistance
from rest; GCY-F = great cardiac vein flow (ml/min): %6GCY-F = percent change in great cardiac vein flow from rest; HR = heart rate (beats/min).
experienced chest pain at higher pacing rates (Fig. 1A).
Figure I and Table I indicate that patients experiencing
chest pain during a paced heart rate of 150 beats/min (130
in three patients because of atrioventricular block) achieved
a lower great cardiac vein flow (85 ± 41 mllmin) than did
patients not experiencing chest pain (117 ± 37 ml/rnin, p
< 0.05).
Figure 2 demonstrates the percent change in great car-
diac vein flow from baseline to the maximal paced heart
rate, Those patients experiencing chest pain during pacing
demonstrated a smaller increase in great cardiac vein flow
from baseline than did those patients not experiencing chest
pain (45 ± 30 versus 86 ± 50%, p < 0,025). Additionally,
the calculated coronary resistances (Table I) of the two
groups (chest pain versus no chest pain) during pacing were
significantly different (1.35 ± 0.52 versus 0.98 ± 0.37
mm Hg/ml per min, p < 0.05). Those patients with chest
pain had a smaller decrease in resistance (- 23 ± 18%)
from baseline (Fig. 2) than did patients without chest pain
(-44 ± 11%, P < 0.001). Lactate consumption (Fig. 3)
during pacing was less in patients with chest pain during
pacing than in patients without pain (25.0 :t 23.6 versus
45.6 ± 19,0 mrnol-ml/rnin, p < 0.025), with two patients
demonstrating a marked decrease in lactate consumption
during pacing. No significant ST segment abnormalities were
noted on monitor leads during pacing in either group.
Cold pressor test. The baseline variables of heart rate,
blood pressure, great cardiac vein flow and coronary resis-
tance remained unchanged in this study (Table 2) compared
with the control study (Table I). In the group that experi-
enced no chest pain during the cold pressor test study, cold
pressor testing at rest resulted in a significant increase in
mean blood pressure ( + 12 ± 8%, p < 0.001) and great
cardiac vein flow ( +27 ± 25%, p < 0.001) and decrease
in coronary resistance (-12 ± 15%, P < 0.001) from
baseline measurements (Fig. 4). However, despite a similar
increase in blood pressure during cold pressor testing at rest,
the group that would experience chest pain during subse-
quent pacing demonstrated no significant increase in great
cardiac vein flow or decrease in coronary resistance. Figure
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Figure 1. Great cardiac vein (GCY) flow duringcontrol study in
each patient in study at rest and during coronary sinus pacing
(beginning at 100 beats/min). A, Patients developing chest pain.
B, Patients not developing chest pain. Numbers in figure indicate
case numbers; large circles with bars indicate mean value.
2 shows the percent change in great cardiac vein flow and
coronary resistance between the baseline measurement and
that of the cold pressor test with pacing to the same final
heart rate as in the control study.
Although no patient experienced chest pain during the
cold pressor test at rest, eight patients experienced chest
pain with pacing during the cold pressor test, including two
additional patients who did not experience chest pain with
pacing during the control study. The peak great cardiac vein
flow at maximal pacing (Table 2) was significantly lower
(87 ± 26 versus 124 ± 34 mllmin, p < 0.05) and increased
less from baseline (44 ± 19 versus 89 ± 40%, P < 0.001)
(Fig. 2) in the group of patients with chest pain. With
pacing, the coronary resistance decreased significantly less
in those patients developing chest pain ( - 19 ± 5% versus
38 ± 13%, p < 0.001) (Fig. 2). The difference in lactate
consumption (Fig. 3) was also significant with less lactate
consumption in those without chest pain (32.2 ± 17.3 ver-
sus 62.2 ± 39.2 mmol-rnl/min, p < 0.025), and an actual
decline in lactate consumption occurred in three patients.
No significant 5T segment changes were noted in either
group during pacing.
Selective left and right coronary arteriography per-
formed during the repeat cold pressor test demonstrated no
evidence of focal coronary spasm and only minimal epi-
cardial coronary artery luminal narrowing ( - 5 ± 4% lu-
minal diameter narrowing from control arteriograms).
Ergonovine test study. Repeat baseline measurements
of blood pressure, heart rate, great cardiac vein flow and
coronary resistance (Table 3) were essentially unchanged
from those of the control study (Table I). Ergonovine, 0.15
mg, was administered intravenously to 20 patients, 2 of
whom (Patients 4 and 21) experienced spontaneous chest
pain (Table 3). Their decrease in great cardiac vein flow
(- 21 and - 13%, respectively) and increase in resistance
(+ 39 and + 26%, respectively) was greater than in any
other patient receiving ergonovine. Immediate coronary ar-
teriography demonstrated only minimal epicardial coronary
artery luminal diameter narrowing ( - 5 and - 8%, respec-
tively, from control arteriograms). The group that experi-
enced chest pain during ergonovine infusion at rest or with
subsequent pacing demonstrated a significant increase in
coronary resistance (+ 13 ± 22%, P < 0.05) during er-
gonovine at rest (Fig. 5) despite a significant increase in
blood pressure ( + 7 ± 3%, P < 0.001) from baseline mea-
surements. With a similar increase in blood pressure during
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Figure 2. Percent change (,6) in great cardiac vein (GCV) flow
(A) and coronary resistance (8) during pacing from the rest base-
line control for each respective study. CPT = cold pressor test;
p = probability.
ergo novi ne infusion, the gro up that experienced no chest
pain during the entire ergonovine study demonstra ted no
significant change in great cardiac vein flow or coro nary
resista nce from base line meas ureme nts.
After repeat baseline measurements , the 18 patients who
did not experience chest pain at rest underwent pacing. At
the final pacing rate , those patient s who experienced chest
pain demonstrated a significan tly lower great cardiac vein
flow (106 ± 35 versus 143 ± 34 ml/rnin, p < 0 .025) and
less of an increase in flow from basel ine (38 ± 12 versus
126 ± 68%, p < 0.001), a higher coro nary resis tance (1. 14
± 0.38 versus 0 .84 ± 0.15 mm Hg/m l per min, p < 0.05)
and less of a decrease in resistance ( - 18 ± 4 versus - 50
± 13%, p < 0 .00 1) compare d with those who did not
experience chest pain (Fig. 2 and Table 3) . Lactate con-
sumption tended to decrease in the chest pain group, whereas
it increased in patients with no chest pain (Fig. 3) . The
difference during pacing betw een the two groups was sta-
tistically significant (32.7 ± 25.2 versus 70.1 ± 29.4
mmol-rnl/min, p < 0.01) . No significant ST segment changes
were noted during ergonovine testing, rest or pacing in either
grou p.
Selec tive coronary arteriography performed immediately
after pacing (3 to 4 minutes after ergo novine administration)
showed no focal spasm and only minimal (- 8 ± 6%)
epicardial coronary artery luminal narrowing compared with
control arteriograms .
Dynamic coronary vasoconstriction and altered an-
ginal threshold. During the cold pressor study , six of the
eig ht patient s (Patients 1. 3, 4 , 5, 20 and 2 1) experiencing
chest pain demonstrated an increase in co ronary resistance
(1. 13 ± 0. 3 1 versus 1.0 1 ± 0.3 1 mm Hg/ml per min) at
the onset of pain compared with the value at the onse t of
pain dur ing the cont rol study (or maxim al heart rate if no
chest pain occurred), a change assoc iated with a decrease
in flow (87 ± 26 versus 96 ± 33 ml/rnin) (Fig . 6) . The
rate-pressure product (heart rate x systolic blood pressure)
in these same patients changed insig nifica ntly between the
two studies (14,100 ± 3,000 versus 14 ,800 ± 2,200 , P
= NS) . Similarly, during the ergonovine study, 8 of the
12 patient s (Patients I, 3, 4 , 5, 7 , 18 , 21 and 22) with ches t
pain demonstrated an increase in coronary resistance at the
onset of pain (1.32 ± 0. 38 versus 0.97 ± 26 mm Hg/ml
per min) compared with the value at the control study an-
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Table 2. Hemodynamic Data During Cold Pressor Test Study
Baseline Control CPT Rest CPT Pacing
Case HR BP GCY-F CR HR BP GCY-F o/c6 GCY-F CR o/r6 CR HR BP GCY-F o/c6 GCY-F CR o/r6CR
Group Developing Chest Pain
1 65 88 46 1 91 59 105 59 28 1.78 - 8 130 98 88 82 I I I - 41
2 70 97 53 1.83 73 115 54 2 2 13 16 150 11 3 67 26 1 69 -8
3 75 72 89 0.81 74 77 108 21 0 71 - 12 130 92 133 49 0.69 - 15
4 71 84 81 1.04 67 76 76 - 7 1.00 - 2 150 93 11 6 43 080 -2 1
5 92 87 61 1 43 92 96 66 8 1.45 I 150 97 83 36 I 17 - 18
8 80 95 52 1.83 81 107 81 56 1.32 - 28 140 133 74 42 I 80 - 2
20 77 93 46 2.02 77 100 43 -6 233 14 150 92 t: 57 I 28 -37
21 59 80 47 1.70 65 94 45 - 4 2.09 23 130 88 59 20 1 49 - II
Mean 74 87 59 1.57 74 96 67 12 1.60 +1 141 101 87 44 1 25 - 19
± SD 10 8 17 0.44 10 14 22 22 0.58 17 10 15 26 19 0.40 5
Group Not Developing Chest Pain
6 83 11 2 70 1.60 91 120 74 6 1.62 0 1 50 ~ 126 11 2 60 1.13 - 30
7 85 11 2 71 1.58 102 145 105 48 I 38 - 13 1 5 0~ 130 130 83 1.00 - 37
9 86 90 38 237 87 99 48 26 206 - 12 150 97 70 84 1.39 -42
10 71 89 94 0.95 76 11 0 105 12 1.05 II 150 109 166 77 066 - 31
II 78 118 67 1.76 83 125 78 16 1.60 - 9 150 11 8 105 56 1 10 -38
12 68 117 40 2.93 72 128 47 18 2.72 - 6 140 123 102 155 1.21 -59
13 87 109 53 2.06 92 11 7 63 19 1.86 - 10 150 120 74 40 1 62 - 21
14 87 114 96 1.1 9 104 135 140 46 096 -1 9 150" 125 156 63 080 -33
15 71 108 59 1.83 72 11 5 68 15 1.69 - 8 150" 115 139 136 0.83 - 55
16 95 108 63 1.7\ 87 11 6 59 - 6 I 97 15 150 155 108 71 1.44 - 16
17 66 III 88 1.26 78 122 140 -1 5 0.87 - 31 150 145 181 106 080 - 37
18 78 90 44 2.05 83 90 79 80 1.14 - 43 150 92 121 175 0.76 -62
19 98 106 100 1.06 101 11 5 125 25 0.92 - 13 150 105 165 65 064 - 40
22 83 96 65 1.56 85 108 65 - 5 I 74 12 150 115 III 71 1.04 -33
Mean 81 106t 68 1.71 87 118t 85 20 1.54 - 9 149 120'" 124 :' 89:~ 1.03 - 3X::.
± SD 10 10 2\ 0.29 11 14 32 25 0.53 16 3 16 34 40 0.30 13
P values determined comparing patients developing versus those notdeveloping chest pain. * = p < 0 OS; T = P < 0.0I; t = p < 0 00I.
%6 CR = percent change in coronary resistance from baseline cont rol : CPT = cold pressor test: 9c 6 GCY-F = percent change In great cardiac
vein flow frombaseline control; other abbreviations as In Table I
ginal threshold or maximal heart rate if no chest pain oc- Pulmonary artery wedge pressure and cardiac index
curred), a change associated with a decrease in flow (84 ± during pacing. These variables were measured during peak
25 versus 98 ± 28 m1/min). The rate-pressure product changed pacing for the last eight patients in the study (Table 4); three
insignificantly between the two studies (15,200 ± 5,500 patients experienced no chest pain during any of the studies
versus 15,500 ± 3,4 00. p = NS). Because the rate-pressure and five patients experienced chest pain during one or more
product, which is a rough index of myocardial oxygen con- of the studies, Although patients experiencing chest pain
sumption (MV0 2) , did not decrease in these patients, the tended to demonstrate a higher pulmonary artery wedge
increase in resistances cannot be ascribed to autoregulation. pressure during pacing than patients not experiencing chest
These findings considered with the associated changes in pain, the differences were not significant. The wedge pres-
flows suggest that cold pressor testing and ergonovine in- sure during simultaneous pacing and vasoconstrictor ma-
fusion caused active coronary vasoconstriction that devel- neuvers was higher than during the control study. The car-
oped despite the occurrence of myocardial ischemia. diac index remained unchanged from baseline to peak pacing
Lowering of the anginal threshold. as demonstrated by in all studies.
the development of chest pain at a lower rate-pressure prod-
uct compared with that in the control study, was observed Discussion
in four patients during cold pressor testing and in four pa-
Causes and Mechanisms of the Atypical Chest Paintients during infusion of ergonovine (Fig. 7). Three addi-
tional patients in the ergonovine study developed new onset Many patients presenting with atypical patterns of chest
of chest pain at a similar rate-pressure product as their end pain are found to have normal or near normal coronary
point during the control study. arteries that do not exhibit significant epicardial coronary
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Figure 3. Lactate consumption (arterial- great cardiac vein lac-
tate concentration x great cardiac vein flow) at rest and during
maximal paced heart rate (see Methods) during control, cold pres-
sor test and ergonovine studies.
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Figure 4. Percent change from baseline contrQLin
heart rate (HR), mean arterial blood pressure (SP),
great cardiac vein flow (GCY -F) and coronary re-
sistance (CR) during cold pressor test at rest. NS
not significant.
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Table 3. Hemodynamic Data During Ergonovine Study
Baseline Control Ergonovine-Rest Ergonovine-Pacing
Case HR BP GCY-F CR HR BP GCY-F %.6GCY-F CR %.6CR HR BP GCY-F °k.6GCY-F CF %.6CR
Group Developing Chest Pam
I 58 90 44 2.05 70 102 61 39 1.67 -18 120 121 74 68 164 -20
2 70 97 47 2.06 70 107 47 0 228 7 150 112 64 36 1.75 -15
3 76 80 92 0.87 64 82 83 -10 0.99 14 130 87 128 43 068 -22
4 63 81 80 101 65 90 63 -21 1.43 39
5 94 91 67 1.36 92 99 65 - 3 1.52 12 150 100 86 28 I 16 -15
6 96 108 72 1.50 92 115 66 - 8 1.74 16 150 II 115 95 32 1.21 -19
7 94 115 71 162 93 125 82 15 1.52 -6 150 II 123 92 30 1.34 -17
17 72 115 126 0.91 72 120 117 - 7 1.03 12 150 113 163 29 069 -24
18 82 85 63 I 35 73 90 103 63 0.87 - 35 150 107 90 39 I 19 -12
19 90 100 123 081 95 105 129 5 0.81 0 150 108 165 34 0.66 -19
21 57 82 53 I 55 54 90 46 -13 I 96 26
22 76 100 73 1.37 82 104 65 -II 1.60 18 150 115 104 42 1.11 -19
Mean 77 95 76 1.37 77 102 77 4% 1 45 7% 145 110 106 38°/r I 14 - 18'7<
± SD 14 13 26 042 14 14 27 24 045 20 11 11 35 12 038 4
Group Not Developing Chest Pam
8 78 108 72 1.50 77 110 85 18 1.29 -17 150 123 136 89 090 -40
9 67 91 46 1.98 82 98 49 7 200 I 150 97 131 185 0.74 -63
10 68 89 85 1.05 71 94 84 0 I 12 6 150 97 141 66 069 -35
11 78 125 65 1.92 92 130 105 62 1.24 -36 150 122 128 97 095 -50
13 78 110 48 2.29 83 110 48 0 229 0 150 105 93 94 I 13 -58
14 86 115 95 1.21 83 121 95 5 1.27 5 150'1 125 153 61 082 -32
15 79 110 58 1.90 83 115 58 0 I 98 7 150 d 119 153 164 0.78 -58
16 87 120 60 2.00 63 135 63 5 2 14 7 150 155 212 255 0.73 -64
Mean 78 109 66 1 73 79 114 73 12% 167 -3% 150 118 143';' 126" 0.84" -50"
± SD 7 13 17 0.43 8 14 22 21 0.48 15 0 19 34 68 o 15 13
P values determined comparing panents developmg versus those not developing chest pam: " = p < 0.05: t = P < 0.025, j: = p < 0.001.
AbbreviatIons as in Tables I & 2
narrowing during cold pressor testing or ergonovine infu-
sion. The goal of the present investigation was to determine
whether the chest pain experienced by such patients may be
due to myocardial ischemia, and if so, to ascertain the mech-
anism responsible for the induced ischemia. Patients were
specifically selected to exclude those with classic exertion-
induced angina or classic Prinzmetal's (variant) angina. Thus,
although all patients had chest pain precipitated by exertion
and most also had pain at rest, the patients characteristically
experienced marked variations in the intensity of exercise
necessary to precipitate the pain and no patient exhibited
ST segment shifts when an electrocardiogram was obtained
during pain. When such patients are found at catheterization
to have no significant coronary obstructions and no focal
spasm in response to ergonovine administration, their chest
pain is usually considered to be noncardiac in origin. How-
ever, the results of our study suggest that I) the chest pain
experienced by many of these patients is due to myocardial
ischemia, 2) the ischemia is caused by an abnormal vaso-
dilator reserve (or active vasoconstriction) of the coronary
circulation, and 3) this abnormal response may be due to a
reduced vasodilator response of small coronary arteries (pre-
sumably arterioles) to increases in myocardial oxygen
demands.
Myocardial ischemia due to inadequate vasodilator
reserve. Evidence favoring the first two conclusions is de-
rived from several observations. Many of the patients dem-
onstrated unusual coronary flow responses to pacing. Al-
though the flows in some patients displayed a linear increase
with increasing heart rate and increased by more than 50%
over control flow levels, in many patients coronary flow
either increased by less than 50% during pacing or reached
a plateau at higher pacing rates. Most of these latter patients
experienced chest pain at the higher pacing rates (Fig. I).
The role played by inadequate vasodilator reserve in causing
the chest pain is more easily appreciated by the analysis
depicted in Figure 2. The increase in coronary flow and the
decrease in coronary vascular resistance were significantly
less when heart rate was increased in patients who developed
chest pain than in those who did not. The fact that lactate
consumption in patients with chest pain did not increase,
or actually decreased in response to pacing compared with
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Figure 6. Coronary vasoconstriction in
patients experiencing chest pain during
either the cold pressor test (CPT) or dur-
109 the ergonovine study. Increases in
coronary resistance (A) and decreases in
great cardiac vein (GCV) flow (B) oc-
curred despite insignificant changes in rate-
pressure product (heart rate lHR] x sys-
tolic blood pressure [SSP]) an index of
myocardial oxygen consumption. These
changes were observed in six patients dur-
ing the cold pressor study and in eight
patients during the ergonovine study.
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the increase in consumption exhibited by those without chest
pain (Fig. 3), strongly suggests that the pain these patients
developed was due to myocardial ischemia.
Myocardial ischemia due to active vasoconstriction.
Vasoconstrictor maneuvers often exacerbated or unmasked
the abnormal vasodilator reserve in these patients. Six pa-
tients who did not experience chest pain with pacing during
the control study did develop pain when pacing was applied
during one or both of the vasoconstrictor maneuvers. Each
of these patients also developed a markedly attenuated vaso-
dilator response to pacing (Tables 2 and 3). Two patients
who experienced chest pain during pacing in the cold pressor
study also experienced it at rest, during ergonovine admin-
istration. The pain was associated with a marked decrease
in great cardiac vein flow and an increase in coronary re-
sistance. Although cold pressor testing and ergonovine
Table 4. Pulmonary Artery Wedge Pressure and Cardiac Index Response to Pacing*
Study Baselme Pacing
Pulmonary Artery Wedge Pressure (mm Hg)
Control
Cold pressor test
Ergonovine
8 (range. 4 to II)
10 (range, 7 to 14)
9 (range, 5 to 14)
16 (range. 7 to 25)
19 (range. 9 to 27)
23 (range, 13 to 33)
Cardiac Index (liters/min per m')
Control
Cold pressor test
Ergonovme
2.9 (range. 2.4 to 3.7)
2.9 (range, 2.3 to 3 7)
2.9 (range, 2.4 to 3.5)
3.1 (range. 2.1 to 3.9)
3 0 (range. 2.4 to 3 8)
3 I (range. 2.4 to 3.6)
*Mean values recorded In the last erght consecutIve patIents entered into this study.
1370 J AM COLL CARDIOL
1983:1(6):1359-73
CANNON ET AL
administration at rest resulted in significant alterations in
vasoconstrictor tone, especially in those patients who ulti-
mately experienced chest pain during pacing (Fig. 4 and 5),
substantial overlap of individual data did not allow predic-
tion of the responses to pacing during the vasoconstrictor
stimuli.
Fourteen patients experiencing chest pain during cold
pressor or ergonovine studies did so at lower great cardiac
vein flows and higher resistances at the onset of chest pain
compared with the values they achieved during the control
study (Fig. 6). These changes occurred despite insignificant
alterations in the rate-pressure product. Furthermore, eight
patients demonstrated a reduction in anginal threshold dur-
ing the cold pressor and ergonovine studies (Fig. 7) with
either new onset of chest pain not experienced during the
control study or chest pain occurring at a lower rate-pressure
product than that during the control study. Each of these
findings is compatible with the concept that coronary vaso-
constriction was precipitated by these interventions. This
dynamic reactivity to vasoconstrictor influences probably
explains the characteristic clinical features exhibited by these
patients, namely, the occasional appearance of pain at rest
and the marked variation in the amount of exertion that
precipitates their angina.
Atypical responses to vasoconstrictor maneuvers. A
few responses of patients to pacing during vasoconstrictor
maneuvers cannot be entirely explained. One patient who
developed chest pain during pacing in the control study
experienced no chest pain during the cold pressor or er-
gonovine studies. Another patient who developed chest pain
during the control study and cold pressor test study did not
experience chest pain during the ergonovine study. Two
patients with chest pain during the control and ergonovine
studies did not experience chest pain during the cold pressor
test study. In all cases, however, chest pain, when expe-
rienced, was associated with lower great cardiac vein flow
and higher coronary resistance than during the study in
which chest pain was not experienced. It is unclear why the
cold pressor test and ergonovine failed to elicit vasocon-
strictor responses and chest pain in all patients who expe-
rienced chest pain during the control study. In some patients,
the cold pressor test may be an inadequate vasoconstrictor
stimulus; certainly, ergonovine was a more sensitive ma-
neuver for exacerbating or unmasking abnormal vasodilator
reserve and chest pain. In addition, the hemodynamic re-
sponses to the cold pressor test and ergonovine are complex.
In particular, these interventions cause a systemic hyper-
tensive response that varies in degree from person to person.
An increase in MV02 due to the systemic hypertensive
response to the cold pressor test or ergonovine infusion may
result in an enhancement of local vasodilatory influences
through autoregulatory mechanisms that may attenuate or
reverse any abnormal coronary vasoconstriction that might
otherwise be observed. Nonetheless, the majority of patients
who experienced chest pain did so either in all studies or
during the vasoconstrictor studies.
Vasoconstrictor influences versus autoregulatory
mechanisms. The attenuated decrease in coronary vascular
resistance observed in patients who experienced chest pain
when pacing was performed during cold pressor testing or
ergonovine infusion was probably due to inadequate coro-
nary vasodilator reserve. An alternative mechanism could
be evoked if ergonovine or cold pressor testing reduced
myocardial oxygen consumption during pacing to lower lev-
els than those achieved with pacing during the control study.
Under such conditions, autoregulatory mechanisms would
increase coronary vascular resistance to maintain the balance
between myocardial oxygen supply and demand. However,
several findings argue against this latter possibility. First,
when pacing was carried out during vasoconstrictor inter-
ventions, many patients exhibited nearly equivalent levels
of myocardial oxygen consumption (as estimated by the
product of heart rate and systolic blood pressure) at the onset
of chest pain that were nearly equivalent to those measured
when pacing was carried out at similar rates during the
control study. Despite this, myocardial blood flow was lower
(in 5 of 8 patients during cold pressor testing and in 7 of
12 patients during infusion of ergonovine) and coronary
vascular resistance higher (in 6 of 8 patients during cold
pressor testing and in 8 of 12 patients during infusion of
ergonovine) at the onset of chest pain in most patients who
experienced chest pain. Second, the abnormal lactate con-
sumption occurring in response to pacing during the vaso-
constrictor maneuvers in patients with chest pain (Fig. 3)
suggests the presence of myocardial ischemia. These find-
ings imply that flow was inadequate to meet myocardial
oxygen demands and, therefore, that vasoconstrictor influ-
ences overrode autoregulatory mechanisms that should have
led to a greater decrease in coronary vascular resistance and
thereby to a more marked and adequate increase in flow.
Mechanisms Responsible for Abnormal Coronary
Vasodilator Reserve
Vasoconstriction of smaller arteries or arterioles.
Several possible mechanisms could have been responsible
for the abnormal vasodilator reserve observed in this in-
vestigation, two involving dynamic changes in the coronary
vasculature: spasm of the large epicardial vessels, or va-
soconstriction of smaller arteries or arterioles. No significant
changes in luminal diameter of the epicardial coronary ar-
teries were observed during cold pressor or ergonovine test-
ing. Thus, the attenuated decrease in coronary vascular re-
sistance observed in those patients who developed angina
in response to pacing appears to be due to inappropriate
constriction of vessels too small to be reliably measured by
current techniques. Coronary resistance can increase in re-
sponse to reflex increases in alpha-adrenergic stimulation
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or infusion of alpha-adrenergic agonists (26-31). However,
it had never been demonstrated that vasoconstrictor stimuli
acting at the arteriolar level can actually cause myocardial
ischemia by overriding the powerful autoregulatory mech-
anisms that are "designed" to prevent ischemia. In this
regard, during the course of their studies demonstrating that
cold pressor testing increased calculated coronary vascular
resistance in patients with underlying coronary artery dis-
ease, Mudge et al. (32)observed that several of their patients
developed angina during cold pressor stimulation. Although
these investigators suggested that constriction of coronary
arterioles may have played a role in the increase in coronary
resistance and precipitation of the angina, no studies were
performed to distinguish between large vessel spasm and
arteriolar constriction. Feldman et al. (33), utilizing quan-
titative angiography in patients with significantly diseased
coronary arteries, demonstrated that cold pressor testing
increased coronary vascular resistance and that this increase
was accompanied by only minimal luminal narrowing of
the epicardial coronary vessels. These observations sug-
gested that the increase in resistance was most likely me-
diated by arteriolar constriction; the constriction, however,
occurred in the absence of evidence of myocardial ischemia.
The present study demonstrated an abnormal response of
coronary vascular resistance at a time when patients were
experiencing chest pain. The abnormal changes in lactate
consumption give further support to ischemia as a cause of
this pain. Thus, our data, for the first time, provide strong
evidence indicating that ergonovine infusion, as well as
physiologically activated alpha-adrenergic reflexes (caused
by cold pressor stimulation), can cause coronary arteriolar
vasoconstriction that overrides autoregulatory vasodilator
influences and thereby precipitates or exacerbates myo-
cardial ischemia.
Arteriolar vasoconstriction and ischemia in absence
of electrocardiographic changes. The causal role played
by the small vessels in producing the ischemic pain may
help explain the absence of electrocardiographic abnormal-
ities recorded during episodes of pain during exercise testing
or at rest. Thus, a proximal obstruction due to fixed stenosis
or spasm of a large epicardial vessel renders an entire region
of myocardium ischemic; the large mass of ischemic tissue
undoubtedly contributes to the ease of detecting electrocar-
diographic abnormalities. However, vasoconstriction of
coronary arterioles could involve relatively smaller regions
of the myocardium. The vasoconstrictor response may not
uniformly affect all contiguous arterioles, leading to a sit-
uation in which some myocardial fibers are rendered isch-
emic while adjacent fibers are better perfused. Under such
conditions, electrical abnormalities caused by ischemia may
be much less likely to be detected. In addition, studies
involving both animals (34) and human beings (12) have
shown that when coronary blood flow decreases, alterations
of left ventricular function are observed before the detection
of electrocardiographic changes. Thus, ST segment alter-
ations are not a sensitive indicator of ischemia. Similar
considerations may explain why most patients did not ac-
tually produce lactate during chest pain induced by pacing;
these patients exhibited either a decrease in consumption or
less of the increase that normally occurs during pacing
(Fig. 3).
Abnormal myocardial compressive forces. An alter-
native mechanism to active coronary vasoconstriction as the
cause of the abnormal coronary vasodilator reserve and the
ischemia observed may involve abnormal myocardial com-
pressive forces. Thus, a primary abnormality in myocardial
relaxation or the presence of an underlying but unrecognized
cardiomyopathy may increase myocardial wall tension dur-
ing diastole and thereby interfere with coronary flow. In
this regard, we found that pulmonary artery wedge pressure,
recorded in the last eight patients studied, increased during
atrial pacing (Table 4). If wedge pressure accurately reflects
left ventricular diastolic pressure in these circumstances,
then the increase in wedge pressure could reflect a primary
myocardial abnormality and actually cause the inadequate
coronary vasodilator reserve we observed. This conclusion
may be invalid, however, because such changes could also
be the result of ischemia. The increase in wedge pressure
even in patients not experiencing chest pain, and the fact
that normal response of wedge pressure to atrial pacing is
unknown, further complicates this issue.
Limitations. A potential limitation of this study de-
serves mention. Our calculation of coronary artery resis-
tance assumes that the driving pressure across the coronary
bed either equals the mean blood pressure or that the down-
stream or "back" pressure is so small that it can be ne-
glected. Both assumptions are incorrect, even though the
mean blood pressure has frequently been used in resistance
calculations (27-33). Although increases in left ventricular
filling pressures do influence coronary vascular resistance
because of transmural compressive forces on the intrarnyo-
cardial vascular bed during diastole (35), controversy now
exists as to whether this value truly represents the "back
pressure" that determines the perfusion pressure across the
vascular bed. Unfortunately, there is no method available
to elucidate this issue further in patients. However, the
primary data we recorded, the flow values, reveal that pa-
tients developing chest pain during pacing manifest an in-
adequate myocardial flow increment when myocardial ox-
ygen demand increases. Thus, the major conclusions derived
from our data are not critically dependent on calculated
values of coronary vascular resistance.
Clinical Implications
The results of our study have major clinical implications.
First, inappropriate coronary arteriolar vasodilator reserve
must be considered as playing a role in the precipitation or
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exacerbation of the pain experienced by patients exhibiting
variable threshold angina, including those with rest pain but
without the characteristic electrocardiographic findings of
Prinzmetal's angina. Second, the absence of a "positive"
ergonovine or cold pressor test as traditionally defined (that
is, large vessel spasm demonstrated by angiography) does
not rule out vasoconstrictor-induced chest pain because the
syndrome we have described appears to be mediated by
constriction of vessels too small to be detected by coronary
angiography. Thus, although the angiographic demonstra-
tion of spasm during ergonovine testing in patients with
classic Prinzmetal' s angina is highly sensitive in detecting
spasm (15), it is essentially of no value in detecting the
vasoconstriction present in the patients with variable thresh-
old and rest angina who do not demonstrate the classic
findings of Prinzmetal's angina. Because no patient had an
abnormal electrocardiographic response to exercise (I mm
or greater ST segment depression), this relatively simple
means of detecting myocardial ischemia would also appear
to be of little or no diagnostic help. It is unknown if detecting
abnormalities of left ventricular perfusion or contraction
patterns by nuclear imaging will be more practical and as
sensitive in identifying patients with impaired vasodilator
reserve.
In summary, we have demonstrated that the atypical chest
pain present in many patients who have neither fixed lesions
severe enough to explain their symptoms nor large coronary
artery spasm is caused or exacerbated by inappropriate coro-
nary vasoconstriction of vessels too small to be imaged by
coronary anteriography. The lack of awareness of such a
phenomenon usually leads to the mistaken diagnosis of non-
cardiac pain. The demonstration of inappropriate coronary
vasodilator reserve suggests that such patients may benefit
therapeutically from the administration of coronary vaso-
dilators such as nitrates and calcium antagonists.
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